Singapore attracts Lonza cell therapy investment
This article was originally published in Scrip
Executive Summary
Lonza is to invest around CHF30 million ($27.3 million) in a new facility in Singapore for the contract production of cell-based therapeutics. The plant is scheduled to become operational by mid-2011.